Translational Development Acquisition Corp. 8-K

What Happened

• On May 27, 2026, Translational Development Acquisition Corp. (TDAC) entered into a definitive Agreement and Plan of Merger to combine with ProLogium Holding Inc. under a series of two mergers (the “Business Combination”). The transaction implies an approximately $3.8 billion valuation for ProLogium on a net cash‑free basis and the combined company is expected to be named ProLogium Technology and list on Nasdaq under the ticker PRLG.
• The deal includes a pre-closing recapitalization and share consolidation, conversion of TDAC Class A ordinary shares into Company Class A ordinary shares (one-for-one at the First Merger Effective Time for non-dissenting holders), and conversion of TDAC warrants into Company warrants.

Key Details

• Date filed: May 27, 2026; deal documents and a joint press release were furnished with the 8‑K.
• Implied valuation: approximately $3.8 billion (net cash‑free) per the press release.
• Closing conditions include Nasdaq listing approval, TDAC and ProLogium shareholder approvals, effectiveness of a Securities Act registration statement, Available Cash ≥ $250,000,000, and the surviving company having ≥ $5,000,001 net tangible assets after redemptions.
• Governance & equity mechanics: recapitalization/share consolidation using a “Consolidation Factor,” founder IP compensation reserved at up to 2.5% of fully diluted shares, and a new equity incentive plan totaling up to 12.5% (limited to 6% before PIPE close).
• Lock-ups and sponsor commitments: sponsor agreed to vote in favor of the transaction, not redeem sponsor-held TDAC shares, and (with limited exceptions) not transfer certain securities for 12 months post-close; ProLogium shareholders face post-close lock-ups of 18 months (Founder), 12 months (management), and 6 months (certain investors).

Why It Matters

• This filing announces a transformational merger that would take ProLogium public through TDAC, creating a Nasdaq‑listed company (PRLG) and setting the capital structure and governance terms investors will face post‑closing.
• Key investor risks and milestones are explicit: the transaction requires regulatory and shareholder approvals, a large private financing / cash condition (Available Cash ≥ $250M), and specified net tangible asset and listing conditions—any failure could delay or prevent closing.
• Founder and management equity protections (IP compensation and multi-month lock-ups) plus the planned equity incentive pool affect potential dilution and timing of share availability for trading or resale.